Brand Name

Bepreve

Generic Name
Bepotastine Besilate
View Brand Information
FDA approval date: September 08, 2009
Classification: Histamine-1 Receptor Antagonist
Form: Solution

What is Bepreve (Bepotastine Besilate)?

BEPREVE ® 1.5% is a histamine H 1 receptor antagonist indicated for the treatment of itching associated with signs and symptoms of allergic conjunctivitis. BEPREVE is a histamine H1 receptor antagonist indicated for the treatment of itching associated with allergic conjunctivitis.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

Comparative Effectiveness and Safety of Second-Generation Antihistamines Treatments for Chronic Urticaria: A Network Meta-Analysis.
Comparative Effectiveness and Safety of Second-Generation Antihistamines Treatments for Chronic Urticaria: A Network Meta-Analysis.
Journal: International archives of allergy and immunology
Published: June 03, 2025
Treatment of allergic rhinitis and allergic conjunctivitis.
Treatment of allergic rhinitis and allergic conjunctivitis.
Journal: The Medical letter on drugs and therapeutics
Published: March 28, 2025
The Efficacy of Bepotastine Besilate Compared With Hydroxyzine Pamoate for Preventing Infusion Reactions to the First Dose of Rituximab in Patients With Non-Hodgkin Lymphoma: Protocol for a Phase II, Double-Blind, Multicenter Randomized Trial.
The Efficacy of Bepotastine Besilate Compared With Hydroxyzine Pamoate for Preventing Infusion Reactions to the First Dose of Rituximab in Patients With Non-Hodgkin Lymphoma: Protocol for a Phase II, Double-Blind, Multicenter Randomized Trial.
Journal: JMIR research protocols
Published: November 27, 2023
View All Latest Advances